Abstract：
The current evidence on whether annual diabetic retinopathy (DR) screening intervals can be extended was reviewed. A systematic review protocol was followed (PROSPERO ID: CRD42022359590). Original longitudinal articles that specifically assessed DR screening intervals were in English and collected data after 2000 were included. Two reviewers independently conducted the search and reviewed the articles for quality and relevant information. The heterogeneity of the data meant that a meta-analysis was not appropriate. Twelve publications were included. Studies were of good quality and many used data from DR screening programs. Studies fit into three categories; those that assessed specific DR screening intervals, those that determined optimal DR screening intervals and those that developed/assessed DR screening risk equations. For those with type 2 diabetes, extending screening intervals to 3- to 4-yearly in those with no baseline DR appeared safe. DR risk equations considered clinical factors and allocated those at lower risk of DR progression screening intervals of up to five years. Those with baseline DR or type 1 diabetes appeared to have a higher risk of progression to STDR and needed more frequent screening. DR screening intervals can be extended to 3-5 yearly in certain circumstances. These include patients with type 2 diabetes and no current DR, and those who have optimal management of other risk factors such as glucose and blood pressure.
摘要：
回顾了有关年度糖尿病视网膜病变（DR）筛查间隔是否可以延长的当前证据。遵循系统审查方案（PROSPEROID：CRD420223559590）。专门评估DR筛查间隔的原始纵向文章为英文，并包括2000年后收集的数据。两名审稿人独立进行了搜索，并审查了文章的质量和相关信息。数据的异质性意味着荟萃分析是不合适的。包括12种出版物。研究质量很好，许多使用的数据来自DR筛查计划。研究分为三类；那些评估特定DR筛查间隔的研究，那些确定最佳DR筛查间隔的人和那些建立/评估DR筛查风险方程的人.对于那些患有2型糖尿病的人来说，在没有基线DR的患者中,将筛查间隔延长至3~4年的时间似乎是安全的.DR风险方程考虑了临床因素，并分配了那些风险较低的DR进展筛查间隔长达五年。那些基线DR或1型糖尿病患者似乎有更高的STDR进展风险，需要更频繁的筛查。在某些情况下，DR筛查间隔可以延长至每年3-5次。这些包括2型糖尿病患者和目前没有DR，以及那些对血糖和血压等其他危险因素有最佳管理的人。
